| Editor’s note: Fierce Life Sci will be taking a publishing break for the December holidays. Thanks for a great year, and we’ll be back in your inboxes January 6, 2023. |
|
In today’s clinical landscape, explore complex challenges and innovative strategies to safely deliver lifesaving advanced treatments to patients. Download Now.
|
|
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk Special Report—The highest paid medtech CEOs Pfizer, ripping up its traditional social media playbook, posts a meme hitting back at disinformation GSK pays $170M upfront to continue to ride oligonucleotide wave for years to come Eli Lilly says 4 new launches will help drive its 2023 revenue past $30B Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown J&J leads $85M funding for HistoSonics' tumor-blasting ultrasound amid FDA review UPDATED: As Novo irons out obesity supply wrinkles, blockbuster-to-be Wegovy debuts in Europe Takeda's Poseida partnership starts to pay off with promising hemophilia A gene therapy data |
|
In this white paper, we’ll cover, some of the biggest barriers to reaching diverse patient populations and key opinion leaders, why trust of physicians and investigators within communities and drug companies factor is a critical success factor, and how technology can mitigate this challenge when it comes to clinical trials or with bringing drugs to market. Download now.
|
|
| By Conor Hale,Andrea Park When we added up the salaries, stock options, vested shares and bonuses awarded across the industry, we found some interesting additions to our list of the biggest medtech bigwigs. |
|
|
|
By Nick Paul Taylor Merck & Co. has shown why it bet $250 million on Moderna’s mRNA cancer immunotherapy. Weeks after Merck opted into the program, the partners have revealed the personalized candidate reduced the risk of recurrence or death by 44% when given to melanoma patients in combination with Keytruda. |
By Ben Adams Six pharma companies are on Santa’s naughty list this Christmas. AstraZeneca, Biogen, Daiichi Sankyo, Lundbeck, Novo Nordisk and UCB have all been hit by the U.K.’s drug marketing regulator the PMCPA. |
By Ben Adams You have to double-check that a recent tweet out from Pfizer’s official corporate account was in fact real and not from the slew of imposter accounts set up in recent weeks designed to tweet controversial statements under the guise of an official account. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
By James Waldron GSK has added another oligonucleotide to its pipeline, with potentially plenty more to follow courtesy of a $170 million upfront collaboration with Wave Life Sciences. |
By Zoey Becker As the year wraps up, Eli Lilly has set high ambitions for the year ahead. As the diabetes launch Mounjaro gains steam, the company says it expects total revenues to exceed $30 billion next year. |
By Fraiser Kansteiner It’s official: Just weeks after rare disease drug maker Horizon Therapeutics revealed it was at the heart of a bidding war between Amgen, Johnson & Johnson and Sanofi, Big Biotech Amgen has emerged with a multibillion-dollar M&A victory. |
By Annalee Armstrong Gilead landed its Kite unit at Arcellx to work on a phase 2 multiple myeloma cell therapy, a deal worth $225 million upfront plus a $100 million equity investment. |
By Andrea Park HistoSonics' noninvasive ablation technology directs focused ultrasound toward targeted tissue from outside the body. The company is focusing first on attacking tumors in the liver. |
By Fraiser Kansteiner While Wegovy still hasn’t made its way to the U.K., the obesity med did launch in Novo Nordisk's home market of Denmark Monday, a company spokesperson said over email. |
By Helen Floersh Takeda is seeing some positive signals from its $3.6 billion deal with Poseida Therapeutics with promising preclinical data on the companies’ hemophilia A therapy P-FVIII-101. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| MultimediaPlan Your ASH’22 Attendance In No Time | Interactive Planner Sponsored by: Ferma.AI, a product of ZoomRx |
| PodcastHow can Medical Affairs divisions bring greater value to their organizations and practitioners every day? Sponsored by: Medscape Medical Affairs |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Presented by: Catalent |
| Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
